Advances and perspectives in immunotherapy of melanoma

Annals of Oncology

Volumn 23, Issue SUPPL. 10, 2012, Pages

  Schadendorf, D ^a   Vaubel, J ^a   Livingstone, E ^a   Zimmer, L ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Interferon; Interleukin 2; Ipilimumab; Tremelimumab; Unspecific immunotherapy

Indexed keywords

ALPHA INTERFERON; DACARBAZINE; GANGLIOSIDE GM2; GLYCOPROTEIN GP 100; INTERLEUKIN 2; IPILIMUMAB; MELANOMA ANTIGEN 3; PEGINTERFERON ALPHA; PLACEBO; TICILIMUMAB;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; ENDOCRINE DISEASE; GASTROINTESTINAL DISEASE; HUMAN; IMMUNOPATHOLOGY; LIVER DISEASE; LIVER TOXICITY; LOW DRUG DOSE; MELANOMA; METASTASIS; MONOTHERAPY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN DISEASE; SURVIVAL RATE; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; MELANOMA; NEOPLASM METASTASIS; NEOPLASM STAGING; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84866750889     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds321     Document Type: Article

References (40)

1. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004; 351: 998-1012.
2. Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
3. Garbe C, Eigentler TK, Keilholz U et al. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist 2011; 16: 5-24.
4. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723 Erratum in: N Engl J Med 2010; 363: 1290.
5. Pehamberger H, Soyer HP, Steiner A et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 1998; 16: 1425-1429.
6. Grob JJ, Dreno B, de la Salmonie're P et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. Lancet 1998; 351: 1905-1910.
7. Kirkwood JM, Strawderman MH, Ernstoff MS et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996; 14: 7-17.
8. Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 2002; 20: 1818-1825.
9. Wheatley K, Ives N, Hancock B et al. Does adjuvant interferon-alpha for high risk melanoma provide a worthwhile benefit? A meta-analysis of the randomized trials. Cancer Treat Rev 2003; 29: 241-252.
10. Wheatley K, Ives N, Eggermont AM et al. Interferon-a as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 8526.
11. Kirkwood JM, Manola J, Ibrahim J et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004; 10: 1670-1607.
12. Eggermont AM, Gore M. Randomized adjuvant therapy trials in melanoma: surgical and systemic. Semin Oncol 2007; 34: 509-515.
13. Eggermont AMM, Suciu S, Testori A et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 2012; 48: 218-225.
14. Mocellin S, Pasquali S, Rossi CR et al. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2010; 102: 493-501.
15. Kleeberg UR, Suciu S, Bröcker EB et al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer 2004; 40: 390-402.
16. Eggermont AM, Suciu S, Santinami M et al., EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial: Lancet. 2008; 372: 117-126.
17. Eggermont AM, Suciu S, MacKie R et al. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 2005; 366: 1189-1196.
18. Livingston PO, Wong GY, Adluri S et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994; 12: 1036-1044.
19. Eggermont AMM, Suciu S, Rutkowski P et al. Randomized phase III trial comparing postoperative adjuvant ganglioside GM2-KLH/QS-21 vaccination versus observation in stage II (T3-T4N0M0) melanoma: final results of study EORTC 18961. J Clin Oncol 2010; 28(15s): abstract 8505.
20. Hauschild A, Weichenthal M, Balda BR et al. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. J Clin Oncol 2003; 21: 2883-2888.
21. Legha SS. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy. Semin Oncol 1997; 24(Suppl 4): S39-S43.
22. Schadendorf D, Algarra SM, Bastholt L et al. Immunotherapy of distant metastatic disease. Ann Oncol 2009; 20(Suppl 6): vi41-vi50.
23. Dummer R, Garbe C, Thompson JA et al. Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma. J Clin Oncol 2006; 24: 1188-1194.
24. Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17: 2105-2116.
25. Keilholz U, Martus P, Punt CJ et al. Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplatin. Eur J Cancer 2002; 38: 1501-1511.
26. Keilholz U, Punt CJ, Gore M et al. Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group. J Clin Oncol 2005; 23: 6747-6755.
27. Sasse AD, Sasse EC, Clark LGO et al. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev 2007; 1: CD005413.
28. Korman A, Yellin M, Keler T. Tumor immunotherapy: preclinical and clinical activity of anti-CTLA4 antibodies. Curr Opin Invest Drugs 2005; 6: 582-591.
29. Langer LF, Clay TM, Morse MA. Update on anti-CTLA4 antibodies in clinical trials. Expert Opin Biol Ther 2007; 7: 1245-1256.
30. O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4). A novel strategy for the treatment of melanoma and other malignancies. Cancer 2007; 110: 2614-2627.
31. Fong L, Small EJ. Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment. J Clin Oncol 2008; 26: 5275-5283.
32. Kwon ED, Hurwitz AA, Foster BA et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc Natl Acad Sci USA 1997; 94: 8099-8103.
33. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996; 271: 1734-1736.
34. Phan GQ, Yang JC, Sherry RM et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003; 100: 8372-8377.
35. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364: 2517-2526.
36. Kaehler KC, Piel S, Livingstone E et al. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management. Semin Oncol 2010; 37(5): 485-498.
37. Wolchok JD, Neyns B, Linette G et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 2010; 11: 155-164.
38. Ascierto PA, Marincola FM, Ribas A. Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application. J Transl Med 2011; 9: 196.
39. Ribas A, Hauschild A, Kefford R et al. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma [2008 ASCO Meeting abstract LBA9011]. J Clin Oncol 2008; 26: LBA9.
40. Wolchok JD, Hoos A, O'Day S et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response Criteria. Clin Cancer Res 2009; 15: 7412-7420.